Management of Hepatitis B Virus Infection in Liver Transplant Recipients - European Medical Journal

Management of Hepatitis B Virus Infection in Liver Transplant Recipients

Download PDF
Joy Varghese,1 Jayanthi Venkataraman,1 Mettu Srinivas Reddy,1 Mohamed Rela1,2

No potential conflict of interest.

EMJ Hepatol. ;1:58-67. DOI/10.33590/emjhepatol/10314203.
Cirrhosis, Hepatitis B Virus (HBV), Liver Transplantion, Nucleoside, Nucleotide

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


Hepatitis B virus (HBV)-related liver disease is a common indication for liver transplantation (LT) in Asian countries.1 When left untreated, the overall five-year survival rate in HBV-related cirrhosis is 71%, which in cases of decompensated cirrhosis decreases to 14%.2 In the 1980s, hepatitis B-related acute liver failure and chronic liver disease (CLD) were considered contraindications for LT because of almost universal graft reinfection and high rates of graft and recipient failure (>50%).3-4 These patients had severe and rapidly progressive liver disease with a two-year graft and patient survival of 50% compared to 80% in those transplanted for non-HBV-related CLD.5 As a result, there were fewer LT for HBV liver disease for several years.6 However, with the introduction of nucleoside and nucleotide analogues and the use of intra and post- operative hepatitis B immunoglobulin (HBIG), there was renewed interest in the application of LT in these patients. There was a significant decrease in post-operative HBV recurrence rates.7-9 The current overall survival of patients transplanted for HBV-related cirrhosis has improved to 85% at one year, and 75% at five years.7,10-12 The present review highlights issues pertaining to HBV reinfection and de novo infection in LT recipients with recommendations for its management.

Please view the full content in the pdf above.

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally